Neuland Laboratories Limited, founded on January 7, 1984, is a pharmaceutical company specializing in the manufacturing and sale of bulk drugs, including salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride, and ciprofloxacin. It expanded its operations in the 1990s and 2000s, introducing various new drugs and increasing production capacity with financial assistance from institutions like IDBI. The company exports its products to over 35 countries and has collaborations with multinational firms for specific compounds. In 2012-13, Neuland Laboratories reorganized to focus on its core activities of APIs, intermediates, and contract manufacturing, divesting its R&D and peptide research activities. It has strategic partnerships, including with API Corporation, Japan, and operates subsidiaries in the USA and Japan. In 2018, Neuland Laboratories completed a merger with Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited, consolidating its equity structure and expanding its manufacturing capabilities with a new facility.
